Company Overview
| Stock Name | Cryofocus-B |
|---|---|
| Stock Code | 06922 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 主要專注於微創介入冷凍治療領域,核心產品為膀胱冷凍消融系統及內鏡吻合夾,產品組合覆蓋經自然腔道內鏡手術(治療泌尿、呼吸及消化系統疾病)及血管介入療法(治療房顫、高血壓等心血管疾病)。 |
| Listing Date | 2022-12-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區康新公路3399弄15號樓 |
| Business Address (Hong Kong) | 香港銅鑼灣希慎道33號利園一期19樓1901室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.cryofocus.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 18.90 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 200 shares |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2022-12-16 to 2022-12-21 |
| Global Offering Shares | 11,110,000 shares |
| HK Public Offer Shares (Initial) | 1,111,000 shares (10.0%) |
| Public Offer Lots (Initial) | 5,555lots (Pool A2,777lots,Pool B2,778lots) |
| International Placing Shares (Initial) | 9,999,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 239,110,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 209,979,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 0 lots | 5 | HK$ 0 |
| 0 lots | 10 | HK$ 0 |
| 0 lots | 20 | HK$ 0 |
| 0 lots | 25 | HK$ 0 |
| 1 lots | 200 | HK$ 0 |
| 2 lots | 400 | HK$ 0 |
| 3 lots | 600 | HK$ 0 |
| 4 lots | 800 | HK$ 0 |
| 5 lots | 1,000 | HK$ 0 |
| 6 lots | 1,200 | HK$ 0 |
| 7 lots | 1,400 | HK$ 0 |
| 8 lots | 1,600 | HK$ 0 |
| 9 lots | 1,800 | HK$ 0 |
| 10 lots | 2,000 | HK$ 0 |
| 15 lots | 3,000 | HK$ 0 |
| 20 lots | 4,000 | HK$ 0 |
| 25 lots | 5,000 | HK$ 0 |
| 30 lots | 6,000 | HK$ 0 |
| 35 lots | 7,000 | HK$ 0 |
| 40 lots | 8,000 | HK$ 0 |
| 50 lots | 10,000 | HK$ 0 |
| 75 lots | 15,000 | HK$ 0 |
| 100 lots | 20,000 | HK$ 0 |
| 125 lots | 25,000 | HK$ 0 |
| 150 lots | 30,000 | HK$ 0 |
| 250 lots | 50,000 | HK$ 0 |
| 300 lots | 60,000 | HK$ 0 |
| 400 lots | 80,000 | HK$ 0 |
| 500 lots | 100,000 | HK$ 0 |
| 1,000 lots | 200,000 | HK$ 0 |
| 1,250 lots | 250,000 | HK$ 0 |
| 29,590 lots | 5,918,000 | HK$ 0 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 610.2M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +1492% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 4,519,179,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣126.5百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 70,079,000 |
| Listing Expenses / Funds Raised | ~33.37% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2020 |
|---|---|
| Revenue | 9,054 |
| Cost of sales | -4,414 |
| Gross profit | 4,640 |
| Other income and gains, net | 5,283 |
| Selling and distribution expenses | -43,000 |
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 17.66 |
|---|---|
| First Day Open | HK$ 18.5 |
| First Day Change | -6.56% |
| First Day Volume | 771400.0 |
| First Day Turnover | 14154600.0 |
| Use of Proceeds | 1、58.2%或約81.4百萬港元將用于為膀胱冷凍消融系統的研發活動、商業推廣(包括銷售及營銷)及制造提供資金;
2、15.7%或約22.0百萬港元將用于為內鏡吻合夾的研發活動、商業推廣(包括銷售及營銷)及制造提供資金;
3、6.1%或約8.5百萬港元將分配予心臟冷凍消融系統的研發活動、計劃商業推廣及制造;
4、20.0%或約28.0百萬港元將分配予目前產品管線的其余14款在研產品的研發活動、注冊備案、計劃商業推廣及制造。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (4)
Joint Bookrunners (7)
Joint Lead Managers (8)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 李克儉 | — |
| Company Secretary | 劉偉、梁慧欣 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 李女士及呂先生(一致行動人士)緊隨全球發售完成後合共持有約55.60%股份,寧波麟灃及上海仕地為其控制法團;珠海高瓴鈞恒持股約5.66%;蘇州新建元二期創投持股約5.14%。 |
|---|




